Financials data is unavailable for this security.
View more
Year on year Sinphar Pharmaceutical Co Ltd grew revenues 3.72% from 2.86bn to 2.96bn while net income improved 67.01% from 224.64m to 375.17m.
| Gross margin | 39.02% |
|---|---|
| Net profit margin | 11.74% |
| Operating margin | 10.61% |
| Return on assets | 5.71% |
|---|---|
| Return on equity | 11.94% |
| Return on investment | 7.67% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at Sinphar Pharmaceutical Co Ltd fell by 163.07m. However, the company earned 296.37m from its operations for a Cash Flow Margin of 10.00%. In addition the company used 334.56m on investing activities and also paid 120.67m in financing cash flows.
| Cash flow per share | 3.50 |
|---|---|
| Price/Cash flow per share | 10.11 |
| Book value per share | 18.61 |
|---|---|
| Tangible book value per share | 18.18 |
More ▼
Balance sheet in TWDView more
| Current ratio | 2.06 |
|---|---|
| Quick ratio | 1.44 |
| Total debt/total equity | 0.6151 |
|---|---|
| Total debt/total capital | 0.3599 |
More ▼
Growth rates in TWD
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 66.99%. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is the highest in its industry.
| Div yield(5 year avg) | 1.80% |
|---|---|
| Div growth rate (5 year) | 58.49% |
| Payout ratio (TTM) | 46.42% |
| EPS growth(5 years) | 111.82 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 34.50 |
More ▼
